Lineage Cell Therapeutics shares rise 8.12% intraday after partnering with William Demant for hearing loss treatment.

martes, 26 de agosto de 2025, 2:23 pm ET1 min de lectura
LCTX--
Lineage Cell Therapeutics, Inc. rose 8.12% intraday, with the company announcing a partnership with William Demant Invest A/S to advance its auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss. The collaboration involves a multi-year research effort, which is expected to drive the development of novel cell therapies for serious neurological and ophthalmic conditions.

Lineage Cell Therapeutics shares rise 8.12% intraday after partnering with William Demant for hearing loss treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios